Vivesto AB (STO:VIVE)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.0800
-0.0028 (-3.38%)
At close: Mar 9, 2026
-68.00%
Market Cap 91.67M
Revenue (ttm) n/a
Net Income (ttm) -34.08M
Shares Out 1.11B
EPS (ttm) -0.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 679,157
Average Volume 1,301,962
Open 0.0828
Previous Close 0.0828
Day's Range 0.0781 - 0.0828
52-Week Range 0.0736 - 0.3190
Beta 0.97
RSI 42.30
Earnings Date Mar 2, 2026

About Vivesto AB

Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known a... [Read more]

Sector Healthcare
Founded 1988
Employees 4
Stock Exchange Nasdaq Stockholm
Ticker Symbol VIVE
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.